Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuncell-LC in HCC patients post-TACE
NCT02856815Phase 2Completed
- Sponsor
- GC Cell
- Start
- May 2018
- Primary completion
- Aug 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of immuncell-lc in hepatocellular carcinoma (HCC) (2 arms), sponsored by GC Cell. Primary endpoint: Recurrence Free Survival at 12 months. Started May 2018; status: completed.
02
Drugs
immuncell-lc
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02856815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02856815.